evaluate novo nordisk on glp-1 agonists Bolsters Portfolio With OZEMPIC's New Approval Real-World Evaluation of GLP-1 Receptor
Description
Lee SH, Ko HM, Jee W, Kim H, Chung WS, Jang HJ
A systematic literature review and network metaanalysis comparing onceweekly semaglutide with other GLP1 receptor agonists in patients with type 2 diabetes previously receiving 12 oral antidiabetic drugs
Future cohort studies should consider the risk for reverse causation introduced by pancreatic cancer-related diabetes where the diabetes is paraneoplastic in response to the pancreatic tumor 46
The Cleveland Clinic analysis found that many patients who stopped GLP-1 therapy later restarted, sometimes with the same medication, sometimes switching to an alternative
Deganutti, G
